NAMS

NewAmsterdam Pharma Company N.V. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website newamsterdampharma.com
Employees(FY) 22
ISIN NL00150012L7

Performance

+1.63%

+7.69%

+58.78%

+49.04%

+128.29%

YTD

+142.86%

Profile

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Advanced Technical Analysis

Technical Analysis of NAMS 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Technical Score of 68 further supports this positive outlook. However, the Oscillators Score of 46 suggests a neutral stance, indicating potential consolidation or a pause in the upward trend, which investors should monit...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NAMS

Stock Rank

Recent News & Updates

2024-12-13 17:16
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares(GlobeNewswire)
2024-12-13 04:16
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares(Globenewswire)
2024-12-11 21:37
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants(GlobeNewswire)
2024-12-11 15:06
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating(Investor's Business Daily)
2024-12-11 08:37
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants(Globenewswire)
2024-12-10 17:10
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug(Investor's Business Daily)
2024-12-10 16:34
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants(GlobeNewswire)
2024-12-10 07:00
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia(GlobeNewswire)
2024-12-10 03:34
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants(Globenewswire)
2024-12-09 18:00
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia(Globenewswire)
2024-12-06 16:01
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-12-06 03:01
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-11-21 07:37
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results(TipRanks)
2024-11-20 16:13
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study(Investor's Business Daily)
2024-11-20 07:00
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH(GlobeNewswire)
2024-11-19 18:00
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH(Globenewswire)
2024-11-18 15:20
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024(GlobeNewswire)
2024-11-18 02:20
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024(Globenewswire)
2024-11-11 05:43
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate(Simply Wall St.)
2024-11-06 08:00
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results(GlobeNewswire)
2024-11-05 19:00
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results(Globenewswire)
2024-11-01 17:26
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-11-01 05:26
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-10-28 16:30
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November(GlobeNewswire)
2024-10-28 04:30
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November(Globenewswire)
2024-10-08 07:01
Three Undervalued Small Caps In United States With Insider Buying To Consider(Simply Wall St.)
2024-10-07 07:03
Insider Buying Highlights These 3 Undervalued Small Caps In United States(Simply Wall St.)
2024-10-04 16:30
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-10-04 04:30
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-10-02 06:49
Daily – Vickers Top Buyers & Sellers for 10/02/2024(Argus Research)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.